(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Artemis 2 astronauts arrive at Kennedy Space Center ahead of NASA's historic launch around the moon - 2The risk of falling space junk hitting airplanes is on the rise, experts warn
- 3How grandchildren are stepping up to fill the caregiver gap
- 4Europe could get 42 more days of summer by the year 2100 due to climate change
- 55 VIPs That Changed Style
- Heavy rain, floods kill at least 45 people in Afghanistan, Pakistan
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- Born under fire: MDA delivers baby in Jerusalem minutes before rushing to shelter
- The Significance of Prenuptial Arrangements in Separation Procedures
- Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- Solid Propensities: Little Changes for a Superior Life
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- Poland identifies two Ukrainian suspects in railway sabotage blast
- NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
